The Michael J. Fox Foundation Announces Award to Drive Phase IIa Clinical Trial Investigating Potential Safety and Benefit of Nilotinib in PD

(July 28, 2017) - The Michael J. Fox Foundation for Parkinson's Research today announced U.S. Food and Drug Administration (FDA) approval of a multicenter, double-blind, randomized, placebo-controlled Phase IIa clinical trial to test safety and tolerability of nilotinib (Tasigna) in Parkinson's disease (PD). The trial is designed to investigate the potential of repurposing nilotinib, an FDA-approved treatment for chronic myelogenous leukemia, for use in Parkinson's disease. Read more